Gene therapy: Difference between revisions
imported>Anthony.Sebastian (fleshing out introduction) |
imported>Anthony.Sebastian mNo edit summary |
||
| Line 7: | Line 7: | ||
</blockquote> | </blockquote> | ||
In 2008, Arthur Nienhuis reported that gene therapy cured 90% of 30 patients with a genetic disorder called severe combined immunodeficiency disease (SCID), children who cannot ward off routine infections and die in childhood (bubble-boys). The gene therapists inserted the therapeutic gene in the SCID patients using a category of virus known as retroviruses, which have an easy time inserting their genes among the DNA of the patient. <ref name=nienhuis2008molrx>Nienhuis A. (2008) [http://dx.doi.org/10.1038/mt.2008.94 The Growing Clinical Impact of Gene Therapy.] ''Mol Ther'' 16:995-996</ref> The method has the possibility the retrovirus will insert its genes where it can adversely affect other genes and cause leukemia. Fortunately the risk seems small, and the leukemia mostly curable. With larger numbers of patients treated and followed throughout their life, gene therapist can assess the full potential for cure and for adverse effects in SCID. | In 2008, Arthur Nienhuis reported that gene therapy cured 90% of the 30 treate patients with a genetic disorder called severe combined immunodeficiency disease (SCID), children who cannot ward off routine infections and die in childhood (bubble-boys). The gene therapists inserted the therapeutic gene in the SCID patients using a category of virus known as retroviruses, which have an easy time inserting their genes among the DNA of the patient. <ref name=nienhuis2008molrx>Nienhuis A. (2008) [http://dx.doi.org/10.1038/mt.2008.94 The Growing Clinical Impact of Gene Therapy.] ''Mol Ther'' 16:995-996</ref> The method has the possibility the retrovirus will insert its genes where it can adversely affect other genes and cause leukemia. Fortunately the risk seems small, and the leukemia mostly curable. With larger numbers of patients treated and followed throughout their life, gene therapist can assess the full potential for cure and for adverse effects in SCID. | ||
Nienhuis also pointed out that gene therapists have targeted a wide range of medical conditions for gene therapy application: | Nienhuis also pointed out that gene therapists have targeted a wide range of medical conditions for gene therapy application: | ||
Revision as of 20:56, 19 July 2008
According to hematologist Arthur Nienhuis, former president of the American Society of Gene Therapy, gene therapy:
....is the addition of new genes to a patient’s cells to replace missing or malfunctioning genes. Researchers typically use a virus to carry the genetic cargo into cells, because that is what viruses evolved to do with their own genetic material.[1]
In 2008, Arthur Nienhuis reported that gene therapy cured 90% of the 30 treate patients with a genetic disorder called severe combined immunodeficiency disease (SCID), children who cannot ward off routine infections and die in childhood (bubble-boys). The gene therapists inserted the therapeutic gene in the SCID patients using a category of virus known as retroviruses, which have an easy time inserting their genes among the DNA of the patient. [2] The method has the possibility the retrovirus will insert its genes where it can adversely affect other genes and cause leukemia. Fortunately the risk seems small, and the leukemia mostly curable. With larger numbers of patients treated and followed throughout their life, gene therapist can assess the full potential for cure and for adverse effects in SCID.
Nienhuis also pointed out that gene therapists have targeted a wide range of medical conditions for gene therapy application:
Cancer, genetic disorders, immunologic disorders such as graft -vs.-host disease, neurodegenerative disorders, and infectious diseases, including AIDS, have all become targets for gene therapy applications.
Some target specifically diseases resulting from genetically defective bone marrow cells, which provide the for red blood cells and other elements of blood and the cells that maintain bone as a healthy organ. They do bench gene therapy by inserting genes in immature bone marrow cells harvested from the patient, then replace the genetically modified immature bone marrow cells so that they can ultimately replace all the defective cells in the bone.
Numerous serious genetic diseases result from defects in mitochondrial genes.[3] Scientists have begun developing gene therapy methods for diseases caused by defective mitochondrial genes. [4]
References
- ↑ Nienhuis A. (2008) How does gene therapy work? Scientific American. August, page 108.
- • Arthur Nienhaus , former president of the American Society of Gene Therapy, holds a position as hematologist at St. Judes Children’s Research Hospital, Memphis, Tenn
- ↑ Nienhuis A. (2008) The Growing Clinical Impact of Gene Therapy. Mol Ther 16:995-996
- ↑ Dimauro S, Hirano M, Schon EA. (2006) Mitochondrial Medicine. Abingdon, Oxon: Informa Healthcare. ISBN 978-1-84214-288-2.
- • Table of contents: Introduction : the birth of mitochondrial medicine; The mitochondrial respiratory chain and its disorders; Mitochondrial neurology I : encephalopathies; Mitochondrial neurology II : myopathies and peripheral neuropathies; Mitochondrial cardiology; Mitochondrial ophthalmology; Mitochondrial gastroenterology; Mitochondrial otology; Mitochondrial endocrinology; Mitochondrial nephrology; Mitochondrial hematology and oncology; Mitochondrial reproductive medicine; Mitochondrial psychiatry; Mitochondrial dysfunction and neurodegenerative disorders; Therapeutic approaches.
- ↑ Kyriakouli DS, Boesch P, Taylor RW, Lightowlers RN. (2008) Progress and prospects: gene therapy for mitochondrial DNA disease. Gene Ther 15: 1017-1023; advance online publication, May 22, 2008. (Full-Test Free)